Fig. 1

23

0879301 "80 hE6780



Fig. 2

0879394 .06039

(i) TATGACTTGGATGGGAGACCGCCTGG
ACTGAACCTACCCTCTGGCGGACCTTAA –(B)

(ii) TATATAGCGTGGGCGTATATA
ATATATCGCACCCGCATATATGCG –(B)

(iii) TATATAGCGXXXGCGTATATA
ATATATCGCXXXCGCATATATGCG –(B)

Fig. 3

OLIGONUCLEOTIDE LIBRARY

Fig. 4





Fig. 5A



Fig. 5B

Fig. 5
SHEET 1



4/24/98 Fig. 5C



Fig 5D

4/24/98

Fig. 5

SHEET 2



Fig. 5E



Fig. 5F

Fig. 5

SHEET 3

0879348 060397

1	*BCR - ABL*	TTC CAT GGA GAC GCA G AA GCC CTT CAG CGG CCA
2	*BCR*	TTC CAT GGA GAC GCA G gt gag ttc ctc acg cca
3	*ABL*	ccc ctt tct ctt cca g AA GCC CTT CAG CGG CCA

Fig.6

Z6E090' 80hE6Z80



Fig. 7



Fig. 8



Ba/F3

Ba/F3+p190

Ba/F3+p210

(Ba/F3+p210)+anti $p190^{BCR-ABL}$ peptide

(Ba/F3+p190)+anti $p190^{BCR-ABL}$ peptide

Fig. 11

SUBSTITUTE SHEET (RULE 26)



Fig. 13

∠6E090° 80hE6∠80



Fig. 15




1
2
3
4
5
6
7
8
fold induction of CAT
60
50
40
30
20
10
0
pMCAT3
pMCAT6BA
pMCAT6A
pMCAT6B
pMCAT6B + pZN1A
pMCAT6A + pZN1A
pMCAT6BA + pZN1A
pG5EC+pM1V P16

Fig. 9

WO 2004/065397 PCT/US2004/000780

Fig. 10



Fig. 12